NeuroMetrix to be Acquired by electroCore

NURO 12.17.2024

Full Press ReleaseSEC FilingsOur NURO Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - NeuroMetrix to be Acquired by electroCore
  • 11.05.2024 - NeuroMetrix Reports Q3 2024 Business Highlights

Recent Filings

  • 12.30.2024 - 8-K Current report
  • 12.19.2024 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 12.17.2024 - EX-99.1 EX-99.1
PDF Version
NeuroMetrix shareholders to receive cash and Contingent Value Rights

WOBURN, Mass.,Dec. 17, 2024(GLOBE NEWSWIRE) --NeuroMetrix, Inc.(“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, will acquireNeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025.

Under the terms of the merger agreement, a subsidiary of electroCore will merge withNeuroMetrixandNeuroMetrixwill become a wholly owned subsidiary of electroCore. The shareholders ofNeuroMetrixwill be entitled to receive the equivalent of the balance of NeuroMetrix’s net cash at the closing of the transaction, subject to certain adjustments and deductions. Assuming the transaction closes onMarch 31, 2025,NeuroMetrixestimates that the balance of net cash to be paid to its shareholders, after deduction of, among other things, transaction expenses, severance costs, and accrued liabilities, will be approximately$9Min the aggregate. The final balance of net cash will be determined at the time of closing and will be based on a formula set out in the merger agreement.

NeuroMetrixshareholders will also receive one non-tradeable contingent value right (a “CVR”) per share ofNeuroMetrixcommon stock. Each CVR will represent the right to receive (i) certain future net proceeds from any divestiture of the Company’s DPNCheck®platform that is consummated prior to the closing of the transaction with electroCore and (ii) certain royalties, up to an aggregate maximum of$500,000, on net sales of prescription Quell®products over the first two years following the closing of the transaction.

“This announcement represents the culmination of our strategic review process announced inFebruary 2024, and marks a positive outcome for the Company’s shareholders. Through this transaction, we will efficiently return balance sheet cash to our shareholders while providing potential upside through the CVR,” saidShai N. Gozani, M.D., Ph.D., Chairman and CEO ofNeuroMetrix. “A further advantage of this transaction is that we expect patients with chronic pain to have expanded access to our novel and proprietary Quell wearable neuromodulation technology through the commercial channel that electroCore has built. Although the DPNCheck platform is not included in the acquisition, we expect to divest this business such that patients and physicians continue to benefit from its unique and important diagnostic capabilities.”

Consummation of the transaction is subject to approval by the shareholders ofNeuroMetrix,NeuroMetrixhaving at least$8 millionof net cash at closing, and the filing of NeuroMetrix’s Form 10-K with respect to the fiscal year endedDecember 31, 2024, in addition to certain customary closing conditions.

AboutNeuroMetrix

NeuroMetrixis a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell®is a wearable neuromodulation platform. DPNCheck®is a point-of-care screening test for peripheral neuropathy. For more information, visitwww.neurometrix.com.

About electroCore

electroCore is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Its focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance inthe United Statesand select overseas markets.

Safe Harbor Statement

The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include information concerning possible or assumed future results of operations of the Company, the expected completion and timing of the transaction and other information relating to the transaction. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “forecasts,” “should,” “estimates,” “contemplate,” “future,” “goal,” “potential,” “predict,” “project,” “projection,” “may,” “will,” “could,” “should,” “would,” “assuming” and similar expressions are intended to identify forward-looking statements. You should read statements that contain these words carefully. They discuss the Company’s future expectations or state other forward-looking information and may involve known and unknown risks over which the Company has no control. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the Company’s business and the price of the common stock of the combined company following the merger, (ii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the merger agreement by the stockholders of the Company and the receipt of any required regulatory approvals from various governmental entities (including any conditions, limitations or restrictions placed on these approvals) and the risk that one or more governmental entities may deny approval, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) the risk that the merger agreement may be terminated in circumstances that require the Company to pay a termination fee; (v) risks regarding the failure to obtain the necessary financing to complete the merger, (vi) the effect of the announcement or pendency of the transaction on the Company’s business relationships, operating results and business generally, (vii) risks that the proposed transaction disrupts current plans and operations, (viii) risks related to diverting management’s attention from the Company’s ongoing business operations, and (ix) the outcome of any legal proceedings that may be instituted against the Company related to the merger agreement or the transaction. . There can be no assurance that future developments will be those that the company has anticipated. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are described in the company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with theSecurities and Exchange Commission(the “SEC”) or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.

Additional Information and Where to Find It

In connection with the transaction, the Company intends to file relevant materials with theSEC, including a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with theSEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT THE COMPANY OR ELECTROCORE WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PARTIES AND THE TRANSACTION. The definitive proxy statement, the preliminary proxy statement and other relevant materials in connection with the transaction (when they become available), and any other documents filed by the Company or electroCore with theSEC, may be obtained free of charge at the SEC’s website (http://www.sec.gov). In addition, materials filed by the Company may be obtained on the Company’s websiteneurometrix.com, and materials filed by electroCore may be obtained on electroCore’s website atwww.electroCore.com.

Participants in the Solicitation

The Company and each of its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders with respect to the merger. Information about the Company’s directors and executive officers and their ownership of the Company’s common stock is set forth in the proxy statement on Schedule 14A filed with theSEConMarch 27, 2024and the Company’s Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023filed with theSEConMarch 1, 2024. To the extent that such individual’s holdings of the Company’s common stock have changed since the amounts included in the Company’s Annual Report on Form 10-K for the fiscal year endedDecember 31, 2023filed with theSEConMarch 1, 2024, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with theSEC. Information regarding the identity of the potential participants, and their direct or indirect interests in the merger, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed withSECin connection with the merger.

Source:NeuroMetrix, Inc.

Thomas T. HigginsSVP and Chief Financial Officerneurometrix.ir@neurometrix.com

Primary Logo

Source: NeuroMetrix, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com